Key result
ViV-TAVR offers a safe, minimally invasive reintervention strategy for failed surgical bioprosthetic aortic valves.
Why the study?
Valve-in-valve transcatheter aortic valve replacement has emerged as a key reintervention strategy for failed surgical bioprostheses requiring meticulous preprocedural planning to optimize outcomes.
Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is an important and growing minimally invasive reintervention strategy for failed surgical bioprostheses that requires meticulous preprocedural planning.
Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) has emerged as a key reintervention strategy for failed surgical bioprostheses. Meticulous preprocedural planning with computed tomography, fluoroscopy, and transesophageal echocardiography is essential for optimal outcomes. Emerging artificial intelligence-based technologies may help mitigate associated risks such as coronary obstruction and patient-prosthesis mismatch and assist with lifetime management planning for valvular heart disease. Transcatheter valve underexpansion can be addressed through bioprosthetic valve fracture in select cases. ViV-TAVR is likely to continue to grow in prevalence given an aging population, its minimally invasive nature compared to redo surgical aortic valve replacement, and its favorable safety profile.
No takes yet. Share an insight, caveat, or question.
Proshkina et al. (2026) conducted a review in Failed surgical bioprostheses. Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) was evaluated. Valve-in-valve transcatheter aortic valve replacement is an important minimally invasive reintervention strategy for failed surgical bioprostheses with a favorable safety profile.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: